Harmony Biosciences Holdings Inc. (HRMY): Price and Financial Metrics


Harmony Biosciences Holdings Inc. (HRMY): $31.99

-0.65 (-1.99%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

HRMY Stock Price Chart Interactive Chart >

Price chart for HRMY

HRMY Price/Volume Stats

Current price $31.99 52-week high $52.74
Prev. close $32.64 52-week low $25.46
Day low $31.86 Volume 171,100
Day high $32.84 Avg. volume 159,304
50-day MA $29.83 Dividend yield N/A
200-day MA $35.65 Market Cap 1.82B

Harmony Biosciences Holdings Inc. (HRMY) Company Bio


Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product WAKIX is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded on July 25, 2017 and is headquartered in Plymouth Meeting, PA.


HRMY Latest News Stream


Event/Time News Detail
Loading, please wait...

HRMY Latest Social Stream


Loading social stream, please wait...

View Full HRMY Social Stream

Latest HRMY News From Around the Web

Below are the latest news stories about Harmony Biosciences Holdings Inc that investors may wish to consider to help them evaluate HRMY as an investment opportunity.

/C O R R E C T I O N -- Harmony Biosciences/

Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced results of a new analysis evaluating number needed to treat (NNT) and effect sizes for treatment with WAKIX® (pitolisant) that demonstrates the magnitude of its clinical effectiveness for excessive daytime sleepiness (EDS) and cataplexy in adults w

Yahoo | June 10, 2021

Harmony Biosciences Announces Applications for 2021 Patients At The Heart Grant Program Open June 9

PLYMOUTH MEETING, Pa. , June 9, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ: HRMY ), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced applications for its Patients at the Heart Grant Program open Wednesday, June 9, 2021 for patient-centric organizations working to support and address the challenges of people living with sleep disorders and rare diseases who experience excessive daytime sleepiness (EDS). … Full story available on Benzinga.com

Benzinga | June 9, 2021

Harmony Biosciences To Present New Data Analyses For WAKIX® (pitolisant) At The SLEEP 2021 Annual Meeting

Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced that results from two post-hoc analyses from the clinical development program for WAKIX® (pitolisant) will be presented at the 35th Annual Meeting of the Associated Professional Sleep Societies (APSS), known as "SLEEP 2021." The meeting will be hel

Yahoo | June 7, 2021

Harmony Biosciences to Participate in Three Investor Conferences in June

Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced that Harmony's President and CEO, John Jacobs, will participate in fireside chats and host investor meetings at the following upcoming virtual conferences:

Yahoo | May 26, 2021

Harmony Biosciences: Looking Very Compelling Here

Photo by oatawa/iStock via Getty Images Harmony Biosciences (HRMY) is a name that went public late in 2020 and attracted my interest from the get go. Harmony went public back in August and, like so many of the names going public around that time, has now seen a round-trip boom...

The Value Investor on Seeking Alpha | May 14, 2021

Read More 'HRMY' Stories Here

HRMY Price Returns

1-mo 14.74%
3-mo 6.07%
6-mo -19.90%
1-year N/A
3-year N/A
5-year N/A
YTD -11.51%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6494 seconds.